Stock VICO VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up

Vicore Pharma Holding AB Stock

Equities

VICO

SE0007577895

Biotechnology & Medical Research

Market Closed - Nasdaq Stockholm
Other stock markets
 11:29:39 2024-04-26 am EDT 		5-day change 1st Jan Change
17.3 SEK +3.72% Intraday chart for Vicore Pharma Holding AB +6.00% +22.00%
Apr. 04 Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Mar. 19 Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI

Financials

Sales 2024 * 104M 9.51M Sales 2025 * 393M 35.94M Capitalization 1.93B 177M
Net income 2024 * -151M -13.8M Net income 2025 * -166M -15.17M EV / Sales 2024 * 16 x
Net cash position 2024 * 274M 25.02M Net cash position 2025 * 222M 20.28M EV / Sales 2025 * 4.35 x
P/E ratio 2024 *
-12.8 x
P/E ratio 2025 *
-7.74 x
Employees 24
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.02%
More Fundamentals * Assessed data

Chart Vicore Pharma Holding AB

Dynamic Chart

Latest news about Vicore Pharma Holding AB

Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106 CI
Certain Shares of Vicore Pharma Holding AB are subject to a Lock-Up Agreement Ending on 11-SEP-2023. CI
Vicore Pharma's New CEO to Formally Take Office MT
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Vicore Pharma Holding AB Reports Data from EndoPAT® Exploratory Trial CI
More news

Latest transcript on Vicore Pharma Holding AB

Logo Vicore Pharma Holding AB
Vicore Pharma Holding AB - Special Call
More transcripts

Press releases Vicore Pharma Holding AB

Vicore to Present at Upcoming April 2024 Investor Conferences AQ
Vicore to Present at Upcoming Investor Conferences AQ
Vicore to Present at Upcoming Investor Conferences AQ
Notice of annual general meeting of Vicore Pharma Holding AB (publ) AQ
Vicore Announces Presentations at the 2024 American Thoracic Society International Conference AQ
More press releases

Quotes and Performance

1 day+3.72%
1 week+6.00%
Current month+17.85%
1 month+18.01%
3 months+28.34%
6 months+22.87%
Current year+22.00%
More quotes

Highs and lows

1 week
16.30
Extreme 16.3
17.84
1 month
14.18
Extreme 14.18
19.04
Current year
12.84
Extreme 12.84
19.04
1 year
12.36
Extreme 12.36
26.90
3 years
12.20
Extreme 12.2
37.45
5 years
6.82
Extreme 6.82
38.30
10 years
5.70
Extreme 5.7
40.00
More quotes

Managers and Directors - Vicore Pharma Holding AB

Managers TitleAgeSince
Ahmed Mousa CEO
 Chief Executive Officer 40 23-09-08
Hans Jeppsson DFI
 Director of Finance/CFO - 16-12-31
Elin Rosendahl CTO
 Chief Tech/Sci/R&D Officer - 20-11-15
Members of the board TitleAgeSince
Jacob Uno Stanley Gunterberg CHM
 Chairman 57 17-12-31
Johannes G. C. P. Schikan BRD
 Director/Board Member 66 17-12-31
Michael Buschle BRD
 Director/Board Member 64 22-12-31
More insiders

Quotes

Date Price Change Volume
24-04-26 17.3 +3.72% 92,932
24-04-25 16.68 -2.91% 149,676
24-04-24 17.18 -1.49% 96,148
24-04-23 17.44 +2.95% 160,468
24-04-22 16.94 +3.80% 107,729

Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT

More quotes

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Sector
Biotechnology & Medical Research
Calendar
2024-05-02 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.3 SEK
Average target price
61.5 SEK
Spread / Average Target
+255.49%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VICORE PHARMA HOLDING AB Stock Vicore Pharma Holding AB
+22.00% 176M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VICO Stock